Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, septiembre 11
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Opus Genetics Inc
IRD
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.07
0.34
5.93%
al cierre: Sep 10, 5:00 PM EST
$6.07
N/A
After hour: 7:57 PM EST
Get Report
PRO
¿Por qué se mueve?:
Opus Genetics shares are trading higher after the company announced 3- and ...
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Opus Genetics Financials
Opus Genetics (IRD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of $(0.24) per share from
Benzinga Newsdesk
Earnings Summary: Opus Genetics Q4
Benzinga Insights
PRO
Opus Genetics Q4 EPS $(0.21) Misses $(0.12) Estimate, Sales $3.865M Beat $3.649M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 70.73 percent. This is a 83.46 percent increase over losses of $(1.27) per share from
Benzinga Newsdesk
PRO
Opus Genetics Q3 EPS $(0.25) Misses $(0.13) Estimate, Sales $3.079M Beat $3.075M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 13.79 percent increase over losses of $(0.29) per share from
Benzinga Newsdesk
Privacy Manager